Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil

Journal of Internal Medicine

Volumn 240, Issue 6, 1996, Pages 403-404

  Van Puijenbroek, E P ^a   Du Buf Vereijken, P W G ^b   Spooren, P F M J ^b   Van Doormaal, J J ^c  

^a Netherlands Pharmacovigilance F   (Netherlands)

^b Maria Hospital TIlburg   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Adverse effect; Gemfibrozil; Rhabdomyolysis; Simvastatin

Indexed keywords

ACENOCOUMAROL; DICLOFENAC; GEMFIBROZIL; GLIBENCLAMIDE; MEVINOLIN; SIMVASTATIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CASE REPORT; DIABETES MELLITUS; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHABDOMYOLYSIS;

EID: 0030473211     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1996.48879000.x     Document Type: Article

References (4)

1. Deslypere JP, Vermeulen A. Rhabdomyolysis and simvastatin. Ann Intern Med 1991; 114: 342.
2. Kogan AD, Orenstein S. Lovastatin-induced acute rhabdomyolysis. Postgrad Med J 1990; 66: 294-6.
3. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 715.
4. Grundy SM, HMG-CoA reductase inhibitors for treatment of hypercholesterolaemia. N Engl J Med 1988; 319: 24-55.